Adding elotuzumab to standard treatment benefited patients with relapsed and refractory myeloma as it improved progression-free survival rates, a new study reveals.
Patients with relapsed chronic lymphocytic leukemia (CLL) responded well to treatment with a chemotherapy-free combination therapy, a new small clinical trials showed.
Several sleep attributes, such as sleep duration and snoring, may affect survival on breast cancer patients, a new study suggests.
Trabectedin (Yondelis) reduced the risk of disease progression in the largest randomized Phase 3 study ever conducted in patients advanced soft tissue sarcoma.
The drug Akynzeo® gained European approval for the prevention of chemotherapy induced nausea and vomiting (CINV).
Combining the immunotherapies nivolumab and ipilimumab or using nivolumab alone resulted in better survival outcomes in advanced melanoma patients.
The combination of adjuvant chemotherapy with androgen suppression and definitive radiation therapy extended overall survival in patients with high-risk prostate cancer.
Renal cell carcinoma patients treated with the combined therapy of lenvatinib with everolimus survived longer without disease progression, a new study reveals.
Combining chemotherapy, radiation therapy and surgical removal of the lung may be beneficial for metastatic non-small cell lung cancer patients, a new study proposes.
Women with endocrine-resistant metastatic breast cancer managed to keep cancer away longer when treated with the novel drug, palbociclib, a new study shows.
Pembrolizumab (Keytruda) found to be beneficial for advanced head and neck cancer patients as it achieved to reduce tumors in size with mild side effects.
The immunotherapy nivolumab PD-1 found to be an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC) in a phase 3 trial.
The immunotherapy nivolumab proved to be safe and highly effective for patients with advanced liver cancer, an early-stage trial suggests.
An increasing body mass index (BMI) was associated with worse prostate cancer-specific outcomes in patients with localized prostate cancer, a new study reveals.
Female breast cancer survivors were able to lose weight through modest lifestyle changes tackling obesity, a major risk factor for breast cancer, a new study reveals.
Adding the innovative immunotherapy elotuzumab to standard treatment extended the duration of remissions by about five months in patients with relapsed multiple myeloma.
Advanced-stage melanoma patients treated with a genetically-modified form of a herpes virus had an especially prominent improvement in response and overall survival.
Melanoma patients rendered surgically free of disease but still at high risk survived longer without melanoma recurrence with the drug ipilimumab, a new study reports.
Chemotherapy given before surgery to women with advanced ovarian cancer resulted in fewer side effects and a better quality of life, a new trial reveals.
New research has shown that when patients with esophageal cancer are treated with proton therapy, a new type of treatment, they experience fewer side effects.
Pembrolizumab (label name: Keytruda), an immunotherapy agent, has received positive opinion from the European regulators for the treatment of advanced melanoma.
Cancer patients who experience stress and fear of treatment both before and during interventions reduced their stress levels by using stress-relief techniques, a new study shows.
A drug developed 50 years ago and abandoned because it was considered to be too toxic, has extended the life of colorectal cancer patients in a new clinical trial.
Young-adult cancer survivors described a variety of physical and psychological problems related to sexuality in survey conducted to inform sexual health communication issues.
Children who survived cancer may be at increased risk of being obese as adults due to the therapies they received during their youth, scientists say.
Age and body mass index and other gene factors associated with the hot flashes, men with prostate cancer experience when treated with androgen deprivation therapy.
The European regulators have approved Novartis’s drug Zykadia, a treatment for lung cancer patients with a rare genetic mutation.
Amgen's skin cancer immunotherapy was recommended for approval by the FDA regardless of the uncertainties around the design and the results of the key study.
A newer form of a less invasive mastectomy technique was found to be safe and equally beneficial for breast cancer patients compared to more invasive techniques.
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.